Habener, Mosjov and Knudsen win the Lasker award

The current GLP1 receptor agonist boom was made possible by the work of Joel Habener, Lotte Bjerre Knudsen, and Svetlana Mojsov.

Insurers continue to embrace Virtual Healthcare for GLP1s

Omada is moving from virtual health into the wider field of wellness programs, enhancing their offering. We dig into what's changed.

Novo's CEO will testify, but change is unlikely

Novo's CEO goes to congress to testify, but not much is likely to change in the drug's pricing. We dive into some historical context.

Reminder: Ozempic face isn't real

Ozempic face isn't real -- fast weight loss causes changes to the skin, and your face is a prime area that will change.

Amgen's GLP1: MariTide (formerly AMG-133)

Amgen is working on a new GLP1, entering the race -- AM-133. We dig into the trials and research and see if it's got any promise.

Eli Lilly's other new GLP1 - Orforglipron

Eli Lilly is developing new GLP1 drugs, and Orforglipron is one of them. It's not easy to pronounce, but it is easy to take, and easy to produce.

GLP1 reverses diabetes in human cells (in mice)

Scientists managed to increase the number of insulin-producing cells in a human-cell-in-mouse experiment.

Thyroid issues with GLP1?

Do GLP1 Receptor Agonists (Ozempic, Wegovy, Mounjaro, Zepbound, and others) cause thyroid issues?

Are GLP1 side effects all the same?

Do some GLP1s have less negative side effects? They work the same, but can affect you differently -- let's look at the research.

23andMe gets into GLP1

23andMe leaves drug discovery, but embraces providing GLP1 Receptor Agonists -- emphasizing a shift to active preventative care.

Systematic reviews of GLP1 worth reading

Want to get refreshed on GLP1 research into drugs like Ozempic, Wegovy, Mounjaro, Zepbound and others? Start here.

Novo's new GLP1: Amycretin

Novo has a new drug it's working on -- Amycretin. Amycretin is a dual agonist, with the *new* agonist being Amylin. Read more about it here.